Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 394 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Open Angle Clear all

Conditions: Glaucoma, Primary Open Angle, Distress, Emotional, Anxiety, Depression
Interventions: Acceptance commitment therapy; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Glaucoma
Interventions: Travoprost 0.004%/timolol maleate 0.5% fixed combination; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: AL-37807; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Open-angle Glaucoma
Interventions: Hydrus Microstent, Ophthalmic surgery; Device · Procedure
Lead sponsor: Ivantis, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 16
States / cities: Fayetteville, Arkansas • Sacramento, California • Fort Collins, Colorado + 13 more

Conditions: Open Angle Glaucoma
Interventions: Transluminal viscoelastic delivery and trabeculotomy; Device
Lead sponsor: Sight Sciences, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 15
States / cities: Dothan, Alabama • Lake Havasu City, Arizona • Fayetteville, Arkansas + 12 more

Conditions: Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma, Pigmentary Glaucoma
Interventions: Hydrus Microstent, iStent Trabecular Micro Bypass; Device
Lead sponsor: Ivantis, Inc.; Industry
Eligibility: 45 Years to 84 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Irvine, California

Conditions: Glaucoma, Glaucoma, Open Angle
Interventions: AqueSys XEN 45 Glaucoma Implant; Device
Lead sponsor: AqueSys, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 12
States / cities: Glendale, Arizona • Fayetteville, Arkansas • Montebello, California + 9 more

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: BOL-303259-X, Timolol; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Alcon Investigational Agent; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Sturge-Weber Syndrome (SWS), Glaucoma, Glaucoma Congenital, Ocular Hypertension
Interventions: QLS-101ophthalmic solution 1%, QLS-101ophthalmic solution 2%; Drug
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Glaucoma
Interventions: Dorzolamide 2%-timolol 0.5%, Brimonidine 0.2%-0.5% timolol 0.5; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 40 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glaucoma, Open-Angle
Interventions: Video education on proper eye drop instillation technique, Placebo video education on healthy eating tips; Other
Lead sponsor: Northwestern University; Other
Eligibility: 40 Years to 85 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Glaucoma, Open-Angle, Hypertension, Ocular
Interventions: NCX 470, Latanoprost 0.005%; Drug
Lead sponsor: Nicox Ophthalmics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Elevated Intraocular Pressure
Interventions: Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005%; Drug
Lead sponsor: TearClear Corp; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 20
States / cities: Garden Grove, California • Glendale, California • Mission Hills, California + 16 more

Conditions: Ocular Hypertension, Open-Angle Glaucoma
Interventions: Latanoprost Punctal Plug Delivery System (L-PPDS); Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 18
States / cities: Chandler, Arizona • Phoenix, Arizona • Torrance, California + 15 more

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: SBI-100 Ophthalmic Emulsion, 0.5%, SBI-100 Ophthalmic Emulsion, 1.0%, SBI-100 Ophthalmic Emulsion, Placebo; Drug
Lead sponsor: Skye Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Glendale, California • Newport Beach, California • Cranberry Township, Pennsylvania

Conditions: Open-Angle Glaucoma
Interventions: Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis; Procedure
Lead sponsor: Barnet Dulaney Perkins Eye Centers; Network
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Mesa, Arizona

Conditions: Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions: REGN22530; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Deerfield Beach, Florida

Conditions: Primary Open Angle Glaucoma
Interventions: GlaucoCetin, Placebo; Dietary Supplement · Other
Lead sponsor: Wills Eye; Other
Eligibility: 40 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma, Ocular Hypertension
Interventions: RKI983; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Timeline: Started 2007
U.S. locations: 5
States / cities: Artesia, California • Rochester, New York • Charlotte, North Carolina + 2 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Brinzolamide/Timolol; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Open Angle Glaucoma, Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigmentary Glaucoma
Interventions: Hydrus Microstent, Ophthalmic surgery; Device · Procedure
Lead sponsor: Alcon Research; Industry
Eligibility: 45 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Bentonville, Arkansas • Zephyrhills, Florida • Fraser, Michigan + 2 more

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension, Elevated Intraocular Pressure
Interventions: ALZ-1101, Latanoprost; Drug
Lead sponsor: Alleanza Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Morrow, Georgia

Conditions: Glaucoma, Open-Angle
Interventions: VVN539 Ophthalmic Solution 0.02%, VVN539 Ophthalmic Solution 0.04%, VVN539 Ophthalmic Solution Vehicle; Drug
Lead sponsor: VivaVision Biotech, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Treating Psychosocial Distress in Glaucoma

Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol

A Phase II Study of AL-37807 to Treat Open-Angle Glaucoma or Ocular Hypertension

Hydrus Microstent for Refractory Open-Angle Glaucoma

Study of OMNI System in OAG (GEMINI)

Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes

AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma

Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41

A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101

Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)

Glaucoma Eye Drop Instillation: Impact of Education

Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma

Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure

Efficacy of Surgical Systems in Combination With Phacoemulsification: a Retrospective Analysis

REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension

Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin

Tolerability, Safety and Efficacy of RKI983 Eye Drops in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension

A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Safety and Effectiveness of the Hydrus Microstent

Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure